Healthcare Stocks

Another feather in Prescient Therapeutics’ (ASX:PTX) cap, bags new US Patent for PTX-100

 Another feather in Prescient Therapeutics’ (ASX:PTX) cap, bags new US Patent for PTX-100

Summary Prescient Therapeutics received new US Patent from the USPTO for companion diagnostic for PTX-100. It is another significant move for PTX in building a deep product pipeline of personalised targeted therapies and tools for treating canc...

Read More...
Opportunities In Personalised Medicine Industry On Prescient’s Radar

Opportunities In Personalised Medicine Industry On Prescient’s Radar

Clinical stage oncology company, Prescient Therapeutics Limited (ASX: PTX) is engaged in developing personalised medicines to treat a range of challenging cancers. The company is known for having one of the deepest clinical pipelines on ASX, with two...

Read More...
Journey of Prescient Therapeutics in 2019

Journey of Prescient Therapeutics in 2019

Prescient Therapeutics Limited (ASX: PTX) is a clinical-stage oncology company that works on mutation causing cancer. The existing product portfolio of the company includes two drug candidates, PTX 100 and PTX 200, under the development phase. Both ...

Read More...
Prescient Therapeutics’ Cancer Trials Backed By A Robust Product Portfolio

Prescient Therapeutics’ Cancer Trials Backed By A Robust Product Portfolio

Clinical stage oncology company Prescient Therapeutics Limited (ASX: PTX) is in the process of developing a breakthrough to traditional therapies by its novel drug candidates that have shown great promise in the treatment of a range of cancers that h...

Read More...
Prescient Therapeutics starts Phase 1b clinical trial of its unique inhibitor PTX-100

Prescient Therapeutics starts Phase 1b clinical trial of its unique inhibitor PTX-100

On 11 July 2019, Prescient Therapeutics Limited (ASX: PTX) announced the commencement of a Phase 1b trial of its second targeted anti-cancer drug PTX-100 in patients with multiple cancers. The trial would reportedly be led by one of the world?s leadi...

Read More...
Prescient Therapeutics’ drug candidates addressing the mutations causing cancer

Prescient Therapeutics’ drug candidates addressing the mutations causing cancer

Clinical-Stage oncology company, Prescient Therapeutics Limited (ASX: PTX) bases the foundation of its business model on the ground-breaking technology that addresses the mutations causing cancer. The company?s mainstream operations are focused on th...

Read More...
All that investors need to know about clinical stage oncology company, Prescient Therapeutics

All that investors need to know about clinical stage oncology company, Prescient Therapeutics

Prescient Therapeutics Limited (ASX: PTX), based in South Melbourne, Australia, is an oncology company (clinical-stage) that develops novel drugs and targeted therapies to treat specific mutations that stimulate cancer and thus, contribute to resista...

Read More...
Prescient Therapeutics Announces The Receipts of R&D Tax Rebate

Prescient Therapeutics Announces The Receipts of R&D Tax Rebate

On 15 January 2019, Prescient Therapeutics Limited (ASX: PTX) announced that the company had received Tax Incentive rebate on research and development for the financial year 2017-2018, amounting to $939,423. The R&D Tax Incentive is an Australian...

Read More...
Ad

GET A FREE STOCK REPORT

Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK